In today’s briefing:
- APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
- Kakaku.com’s 23 Listed Years: What It Got Right, From a Frothy IPO to a Bidding War
APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
- Shionogi is acquiring CNS biopharmaceutical company IntraBio for an upfront consideration of $2B. Ono Pharmaceutical entered exclusive license agreement with Biohaven to develop and commercialize Biohaven’s IgG degrader portfolio.
- Celltrion launched first Xolair biosimilar in the U.S. at 15% discount to the original product. Hanmi Pharmaceutical received domestic marketing approval for Eppe (Epeglenatide), a new GLP-1 class obesity drug.
- CSL is mutually terminating the supply agreement with Terumo and is transitioning to Haemonetics platform. The company stuck new drug development deal with Alentis Therapeutics.
Kakaku.com’s 23 Listed Years: What It Got Right, From a Frothy IPO to a Bidding War
- Kakaku.com returned about 28x with dividends from its first trading day in 2003 to this year’s takeover offers, roughly 15.5% a year, against 8.4% for TOPIX with dividends.
- Early on it grew into a debut priced at 267x earnings, shut its own flagship site after a 2005 breach and launched Tabelog with two staff.
- Later, Tabelog turned reviews into JPY 20bn of reservation fees, return on equity averaged 36% for a decade, and two bidding groups competed for it.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
